Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2025 Earnings Call Transcript November 4, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
Rhythm Pharmaceuticals Inc. (RYTM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 6,666,837 | $713,618,232 | +18% | 7.31% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,604,483 | $599,903,860 | 3.51% | |
| 3. | Perceptive Advisors Joseph Edelman | 2,546,391 | $272,565,693 | +5% | 4.86% |
| 4. | Driehaus Capital Richard Driehaus | 1,285,222 | $137,570,163 | -8% | 0.93% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,185,392 | $126,884,360 | -5% | 0.49% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.17 | 10,000 | $201,713.00 | 111,335 | 2021-03-30 | Filing | |
| $26.42 | 378,501 | $9,999,996.42 | 3,074,893 | 2018-06-25 | Filing | |
| $17.00 | 100,000 | $1,700,000.00 | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 100,000 | $1,700,000.00 | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 550,000 | $9,350,000.00 | 4,909,956 | 2017-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $100.10 | 100 | $10,010.00 | 118,466 | 2026-02-12 | Filing | |
| $98.99 | 800 | $79,192.48 | 118,566 | 2026-02-12 | Filing | |
| $97.67 | 400 | $39,068.52 | 119,366 | 2026-02-12 | Filing | |
| $96.26 | 292 | $28,108.71 | 119,766 | 2026-02-12 | Filing | |
| $100.85 | 100 | $10,085.27 | 120,058 | 2026-02-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,297,334 | $674,066,632 | 0.01% | |
| 2. | 6,210,916 | $664,816,448 | 0.01% | |
| 3. | 3,478,669 | $372,356,730 | 0.28% | |
| 4. | 2,909,956 | $311,481,690 | 15.88% | |
| 5. | 2,198,615 | $235,339,750 | 0.01% |
News See All
Should You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Hot Mid Cap Stocks to Buy Now
On Friday, August 29, stocks declined as investors decided to take some money out before a long weekend.
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript August 5, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals, Inc.
10 Best All-Time High Stocks to Buy According to Analysts
On July 31, Mike Wilson, Morgan Stanley's chief US equity strategist, joined CNBC Television to discuss the market performance amidst inflation concerns.
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00.
Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism
On May 29, analysts at Stifel raised their price target for Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) from $78 to $94 while maintaining their Buy rating for the company's shares.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript May 7, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
Hedge Fund Resource Center Billionaire Hedge Funds
